Eliciting specific antitumor immunity requires the presentation of polypeptide fragments of tumor-associated antigens bound to major histocompatibility complex (MHC) class I or II, in conjunction with co-stimulatory signals to a cognate CD8+ (MHC I bound antigen) or CD4+ (MHC II bound antigen) TCR. This evidence concerns the gene CD8A and neoplasm.